迈向基于证据的非临床路线图以评估新型结核病药物治疗方案的疗效：结核病药物治疗方案关键路径——美国国立过敏与传染病研究所结核病药物开发体内药理学研讨会会议记录
Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development.
作者信息
Nuermberger Eric, Sizemore Christine, Romero Klaus, Hanna Debra
机构信息
Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA.
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2016 Jan 11;60(3):1177-82. doi: 10.1128/AAC.02041-15.
Abstract
Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.
摘要
迫切需要新型结核病（TB）药物治疗方案，而改进的临床前方法将推动其研发，这些方法能更有效地为临床候选药物及药物组合/治疗方案的安全选择提供依据并确保其安全性。美国国立过敏与传染病研究所（NIAID）和结核病药物治疗方案关键路径（CPTR）联盟的联合合作伙伴关系提出了一种基于证据的方法，用于评估支持结核病药物研发的非临床模型。
相似文献
1
Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development.迈向基于证据的非临床路线图以评估新型结核病药物治疗方案的疗效：结核病药物治疗方案关键路径——美国国立过敏与传染病研究所结核病药物开发体内药理学研讨会会议记录
Antimicrob Agents Chemother. 2016 Jan 11;60(3):1177-82. doi: 10.1128/AAC.02041-15.
2
Preclinical Efficacy Testing of New Drug Candidates.新药候选物的临床前疗效测试。
Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0034-2017.
3
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.中空纤维结核系统作为一种新型药物研发工具的战略监管评估和认可。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S5-9. doi: 10.1093/cid/civ424.
4
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发：现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
5
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.全面分析用于评估抗结核分枝杆菌化合物的方法。
Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/j.tube.2012.07.003. Epub 2012 Aug 30.
6
Preclinical study of new TB drugs and drug combinations in mouse models.新型结核病药物及药物组合在小鼠模型中的临床前研究。
Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):102-16. doi: 10.2174/157489108784746579.
7
Research resources for tuberculosis at the National Institute of Allergy and Infectious Diseases.美国过敏和传染病研究所的结核病研究资源。
Tuberculosis (Edinb). 2013 Jan;93(1):6-11. doi: 10.1016/j.tube.2012.11.009. Epub 2013 Feb 4.
8
[Recent progress in mycobacteriology].[分枝杆菌学的最新进展]
Kekkaku. 2007 Oct;82(10):783-99.
9
Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.鼠型结核的病程和一线治疗的反应取决于感染途径和接种物量。
Int J Tuberc Lung Dis. 2011 Nov;15(11):1478-84, i. doi: 10.5588/ijtld.11.0012.
10
Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.实验性结核病的药物治疗：新型二胺类抗生素SQ109与现有结核病药物联合使用可改善治疗效果。
Antimicrob Agents Chemother. 2007 Apr;51(4):1563-5. doi: 10.1128/AAC.01326-06. Epub 2007 Jan 22.
引用本文的文献
1
Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy.化学遗传学相互作用图谱将碳代谢和细胞壁结构与结核病药物疗效联系起来。
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2201632119. doi: 10.1073/pnas.2201632119. Epub 2022 Apr 5.
2
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.基于模型的抗感染药物研发：现状与未来。
Clin Pharmacol Ther. 2021 Apr;109(4):867-891. doi: 10.1002/cpt.2198. Epub 2021 Mar 9.
3
Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.新型结核病药物的研发：向敏感和耐多药结核病的方案组成的转化。
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:495-516. doi: 10.1146/annurev-pharmtox-030920-011143. Epub 2020 Aug 17.
4
OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.新型碳氮唑衍生物 OPC-167832 作为 DprE1 抑制剂具有强大的抗结核活性。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.02020-19.
5
Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.推进新型结核病治疗方案的研发：转化医学与临床药理学及微生物学的重要作用。
PLoS Med. 2019 Jul 5;16(7):e1002842. doi: 10.1371/journal.pmed.1002842. eCollection 2019 Jul.
6
An ADME and Pharmacokinetic Study of Novel TB-Active Decoquinate Derivatives.新型抗结核药地考喹酯衍生物的吸收、分布、代谢和排泄及药代动力学研究
Front Pharmacol. 2019 Feb 18;10:120. doi: 10.3389/fphar.2019.00120. eCollection 2019.
7
Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.结核分枝杆菌中的药物渗透和代谢：将局部暴露作为新结核药物开发的重要标准。
IUBMB Life. 2018 Sep;70(9):926-937. doi: 10.1002/iub.1866. Epub 2018 Jun 22.
8
Improving treatment outcome assessment in a mouse tuberculosis model.提高小鼠结核病模型的治疗效果评估。
Sci Rep. 2018 Apr 9;8(1):5714. doi: 10.1038/s41598-018-24067-x.
9
Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.长效制剂治疗潜伏性结核感染：机遇与挑战。
Int J Tuberc Lung Dis. 2018 Feb 1;22(2):125-132. doi: 10.5588/ijtld.17.0486.
10
Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.使用临床分离的北京株评估小鼠结核病模型中的杀菌药物活性和治疗效果。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00696-17. Print 2017 Oct.
本文引用的文献
1
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.用于确定结核病治疗最佳利奈唑胺方案的临床前评估
mBio. 2015 Nov 3;6(6):e01741-15. doi: 10.1128/mBio.01741-15.
2
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.中空纤维模型预测结核病临床治疗结局的准确性。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S25-31. doi: 10.1093/cid/civ427.
3
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.结核中空纤维模型与结核患者治疗事件的相关性：学习与确认。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S18-24. doi: 10.1093/cid/civ426.
4
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.系统分析结核病实验中空纤维模型。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425.
5
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.C3HeB/FeJ小鼠结核病模型中的异质性疾病进展和治疗反应
Dis Model Mech. 2015 Jun;8(6):603-10. doi: 10.1242/dmm.019513. Epub 2015 Mar 30.
6
Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.抗结核药物的药代动力学-药效学及剂量反应关系：行业与学术界的建议和标准
J Infect Dis. 2015 Jun 15;211 Suppl 3:S96-S106. doi: 10.1093/infdis/jiu610.
7
Nonclinical models for antituberculosis drug development: a landscape analysis.抗结核药物研发的非临床模型：一项全景分析。
J Infect Dis. 2015 Jun 15;211 Suppl 3:S83-95. doi: 10.1093/infdis/jiv183.
8
Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.分析联合药物治疗，以制定缩短结核病治疗疗程的方案。
PLoS One. 2014 Jul 8;9(7):e101311. doi: 10.1371/journal.pone.0101311. eCollection 2014.
9
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.抗结核药物的作用途径：从血液到病灶再到分枝杆菌细胞。
Nat Rev Microbiol. 2014 Mar;12(3):159-67. doi: 10.1038/nrmicro3200. Epub 2014 Feb 3.
10
Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus).结核分枝杆菌复合体感染普通卷尾猴（Callithrix jacchus）后的差异毒力和疾病进展。
Infect Immun. 2013 Aug;81(8):2909-19. doi: 10.1128/IAI.00632-13. Epub 2013 May 28.
Zotero 插件